Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer.

Masiello D, Mohi MG, McKnight NC, Smith B, Neel BG, Balk SP, Bubley GJ.

Cancer Biol Ther. 2007 Feb;6(2):195-201. Epub 2007 Feb 7.

PMID:
17218776
2.

Therapeutic targets: MTOR and related pathways.

Dancey JE.

Cancer Biol Ther. 2006 Sep;5(9):1065-73. Epub 2006 Sep 6. Review.

PMID:
16969122
3.

Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.

Smolewski P.

Anticancer Drugs. 2006 Jun;17(5):487-94. Review.

PMID:
16702804
4.

[Rapamycine and mTOR inhibitors: from bench to bedside].

Pallet N, Beaune P, Legendre C, Anglicheau D.

Ann Biol Clin (Paris). 2006 Mar-Apr;64(2):107-15. Review. French.

5.

Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.

Rao RD, Buckner JC, Sarkaria JN.

Curr Cancer Drug Targets. 2004 Dec;4(8):621-35. Review.

PMID:
15578919
6.
7.

Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option.

Ringshausen I, Peschel C, Decker T.

Leuk Lymphoma. 2005 Jan;46(1):11-9. Review.

PMID:
15621776
8.

Targeting mTOR for cancer treatment.

Rubio-Viqueira B, Hidalgo M.

Curr Opin Investig Drugs. 2006 Jun;7(6):501-12. Review.

PMID:
16784020
9.

Inhibitors of the mammalian target of rapamycin.

Dancey JE.

Expert Opin Investig Drugs. 2005 Mar;14(3):313-28. Review.

PMID:
15833062
10.

Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma.

Costa LJ.

Cancer Treat Rev. 2007 Feb;33(1):78-84. Epub 2006 Dec 11. Review.

PMID:
17161912
11.

Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.

Huang S, Houghton PJ.

Curr Opin Investig Drugs. 2002 Feb;3(2):295-304. Review.

PMID:
12020063
12.

IRS-1: auditing the effectiveness of mTOR inhibitors.

Easton JB, Kurmasheva RT, Houghton PJ.

Cancer Cell. 2006 Mar;9(3):153-5. Review.

13.

Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme.

Panner A, Parsa AT, Pieper RO.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1313-22. Review.

PMID:
17020463
14.

Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications.

Pantuck AJ, Thomas G, Belldegrun AS, Figlin RA.

Semin Oncol. 2006 Oct;33(5):607-13. Review.

PMID:
17045090
15.

Investigating mammalian target of rapamycin inhibitors for their anticancer properties.

Smolewski P.

Expert Opin Investig Drugs. 2006 Oct;15(10):1201-27. Review.

PMID:
16989597
16.

Protein kinase inhibitors.

Shchemelinin I, Sefc L, Necas E.

Folia Biol (Praha). 2006;52(4):137-48. Review.

17.

Mammalian target of rapamycin: a new target in prostate cancer.

Rai JS, Henley MJ, Ratan HL.

Urol Oncol. 2010 Mar-Apr;28(2):134-8. doi: 10.1016/j.urolonc.2009.03.023. Epub 2009 Jun 12. Review.

PMID:
19523861
18.

mTOR and cancer therapy.

Easton JB, Houghton PJ.

Oncogene. 2006 Oct 16;25(48):6436-46. Review.

PMID:
17041628
19.

Protein kinase inhibitors as a therapeutic modality.

Levitzki A.

Acc Chem Res. 2003 Jun;36(6):462-9. Review.

PMID:
12809533
20.

Mammalian target of rapamycin inhibitors in sarcomas.

Okuno S.

Curr Opin Oncol. 2006 Jul;18(4):360-2. Review.

PMID:
16721131

Supplemental Content

Support Center